Structural Formula Of Oxcarbazepine (E8a485af A78b 49a0 9bf4 75e1cd5bb740 01)
Oxcarbazepine
Product Images NDC 21695-864
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 21695-864). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 02)
The given text shows the result of a statistical analysis known as the log-rank test. The p-value obtained from this test is 0.0001, which is a measure of the strength of evidence against the null hypothesis. The remaining text contains a timeline of nine days representing the time on trial from Day 2, with the treatment group being Oxcarbazeping.*
Figure 2 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 03)
The text presents a chart showing the seizure rate over time in days from the first dose to the first seizure for a treatment group that received OXCArbazeping and a group that took placebo. It also includes labels for days and seizure rates on the chart.*
Figure 3 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 04)
This is a survival analysis report that includes a log-rank test with a p-value of 0.0001. There are two treatment groups, HIGH and LOW, and the time for individuals to exit is plotted in days. However, there is some unreadable text in the beginning of the report that cannot be interpreted.*
Figure 4 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 05)
The text describes the statistical analysis of a log-rank test with a p-value of 0.0001. There is also a graph showing the time to exit (in days) for a treatment group with a high and low level.*
Table 3 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 06)
The text describes the influence of oxcarbazepine, an antiepileptic drug, on the concentration of other antiepileptic drugs. It includes information on the mean change in concentration and confidence intervals for carbamazepine, phenobarbital, phenytoin, and valproic acid when coadministered with oxcarbazepine. In general, oxcarbazepine is associated with a decrease in the concentration of these drugs, although there is a mean increase in adults at high oxcarbazepine doses. The text also includes dosing information for the various antiepileptic drugs.*
Table 4 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 07)
The text is readable data on the adverse effects of different doses of Oxcarbazepine (mg/day) on the body system. It includes various categories of adverse events along with the percentage frequency of their occurrence in people taking either 0XC 600, 0XC 1200, 0XC 2400 or a placebo. These categories range from body as a whole, cardiovascular system, digestive system to metabolic and nutritional disorders, musculoskeletal system, nervous system, respiratory system, skin and appendages, and special senses. Specific adverse events are also described, such as hypotension, nausea, vomiting, and fatigue, among others.*
Table 5 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 08)
This is a list of adverse events in patients who took different dosages of Oxcarbazepine. The list includes the percentage of patients who experienced each event while taking 2400 or 300 mg/day. The adverse events are categorized by body system and include symptoms such as headache, dizziness, nausea, vomiting, and urinary tract infection.*
Table 6 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 09)
Table 7 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 10)
This is a list of adverse events and their corresponding percentages for patients who took oxcarbazepine. The adverse events are categorized by body system, including the whole body, digestive system, nervous system, respiratory system, skin and appendages, and special senses. Some of the adverse events reported include fatigue, constipation, headache, and diplopia. The text at the end appears to be a random assortment of characters and is not readable.*
Table 8 (E8a485af A78b 49a0 9bf4 75e1cd5bb740 11)
This is a table showing weight ranges and corresponding dose recommendations for a medication, with the dosage measured in milligrams per day. The weight ranges go from 20 kg to 70 kg, with corresponding doses varying from 600 mg/day to 2100 mg/day. There are also specific recommendations for individuals with different percentages of body weight (2%, 3%, and 5%). The purpose of this table is to guide healthcare providers in prescribing the appropriate dose of medication based on the patient's weight.*
Glenmark Logo (E8a485af A78b 49a0 9bf4 75e1cd5bb740 12)
Oxcarbazepine 300mg (E8a485af A78b 49a0 9bf4 75e1cd5bb740 13)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
